{"id":"p-o-roxithromycin-150-mg-2-d-for-7-days","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Dizziness"},{"rate":"1-3","effect":"Rash"},{"rate":"rare","effect":"QT prolongation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Roxithromycin is a macrolide antibiotic that binds irreversibly to the bacterial 50S ribosomal subunit, blocking translocation of peptides and inhibiting protein synthesis. This bacteriostatic action prevents bacterial replication and allows the immune system to clear the infection. It is effective against a broad spectrum of gram-positive and some gram-negative bacteria, as well as atypical organisms.","oneSentence":"Roxithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:34.318Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Respiratory tract infections (bronchitis, pneumonia)"},{"name":"Skin and soft tissue infections"},{"name":"Otitis media"},{"name":"Sinusitis"},{"name":"Urinary tract infections"}]},"trialDetails":[{"nctId":"NCT02819570","phase":"PHASE4","title":"Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2015-11","conditions":"Premature Rupture of Membrane","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"P.O roxithromycin 150 mg*2/d for 7 days","genericName":"P.O roxithromycin 150 mg*2/d for 7 days","companyName":"Western Galilee Hospital-Nahariya","companyId":"western-galilee-hospital-nahariya","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Roxithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth. Used for Respiratory tract infections (bronchitis, pneumonia), Skin and soft tissue infections, Urinary tract infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}